Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Immucell Corp changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 22 | 27 | +5 |
| Shares | 1.15M | 1.21M | +51.1K (+4.4%) |
| Value | $4.27M | $6.21M | +$1.94M (+45.5%) |
New holders (5)
Institutions that held Immucell Corp at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Dauntless Investment Group, LLC | 131,195 | $675.7K | 2.86% |
| Citadel Advisors LLC | 29,021 | $149.5K | 0.00% |
| Susquehanna International Group, LLP | 11,604 | $59.8K | 0.00% |
| Advisor Group Holdings, Inc. | 391 | $2.01K | 0.00% |
| Capital Advisors, Ltd. LLC | 100 | $1.00K | 0.00% |
Sold out (0)
Institutions that held Immucell Corp at the end of Q3 2024 and filed for Q4 2024 without it.
None.